country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-136109A

Copy Link Print Information

Ulotaront

(別名: SEP-363856; SEP-856)

11 Cited Publications

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

SEP-363856 (SEP-856), an orally active TAAR1 and 5-HT1A agonist and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 (SEP-856) has the potential for the study of schizophrenia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 1310426-33-5
分子式: C₉H₁₃NOS
分子量:183.27

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Ulotaront 構造式

CAS 番号: 1310426-33-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (11)
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

5-HT_1A Receptor

TAAR1

0.140 μM (EC₅₀)

5-HT_1A Receptor

2.3 μM (EC₅₀)

5-HT_1B Receptor

15.6 μM (EC₅₀)

5-HT_1D Receptor

0.262 μM (EC₅₀)

5-HT_2A Receptor

>10 μM (EC₅₀)

5-HT_2C Receptor

30 μM (EC₅₀)

5-HT₇ Receptor

6.7 μM (EC₅₀)

5-HT Receptor アイソフォーム固有の製品をすべて表示 :

体外実験

SEP-363856 (10 μM) shows >50% inhibition of specific binding at α_2A, α_2B, D₂, 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT_2A, 5-HT_2B, 5-HT2C, and 5-HT₇ receptors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

SEP-363856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs^[1].
SEP-363856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity^[1].
Oral SEP-363856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents^[1].
Dosage:

0.3, 1 and 3 mg/kg.
Administration:

Orally once.
Result:

Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F_{(5, 59)} = 18.96, p < 0.0001; Tukey’s post-hoc test, p < 0.05) with a 50% effective dose (ED₅₀) of approximately 0.3 mg/kg.

Animal Model:

Male Sprague Dawley rats^[1].
Dosage:

1, 2, and 5 mg/kg.
Administration:

I.V. injection. (Pharmacokinetic Analysis).
Result:

0.5 hours in mice and rats and maximum plasma concentrations reached within 6 ± 2.83 hours in monkeys.
Penetrated mouse and rat brains after oral administration (10 mg/kg), with average brain-to-plasma AUC ratios of ~3 respectively.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1310426-33-5
分子量 183.27
分子式 C₉H₁₃NOS
SMILES

CNC[C@H]1C2=C(C=CS2)CCO1
別名

SEP-363856; SEP-856
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (11)

All

Sort by:

Journal Impact Factor

Nature

Structural pharmacology and therapeutic potential of 5-methoxytryptamines. [Abstract]

2024 Jun;630(8015):237-246. PMID: 38720072
Nature

Ligand recognition and G protein coupling of trace amine receptor TAAR1. [Abstract]

2023 Dec;624(7992):672-681. PMID: 37935376
Cell

Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. [Abstract]

2023 Nov 22;186(24):5347-5362.e24. PMID: 37963465
Adv Sci (Weinh)

Cortico-Striatal-Midbrain Circuit Dysregulation Underlying MK-801 Induced Impulsivity and the Ameliorative Effects of SEP. [Abstract]

2025 Oct 24:e02079. PMID: 41133933
J Med Chem

Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer's Disease-Related Psychosis. [Abstract]

2025 Apr 10;68(7):7082-7105. PMID: 40159850
Front Pharmacol

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. [Abstract]

2023 Apr 21:14:1161964. PMID: 37153799
Drug Dev Res

SEP-363856 exerts neuroprotection through the PI3K/AKT/GSK-3β signaling pathway in a dual-hit neurodevelopmental model of schizophrenia-like mice. [Abstract]

2024 Jun;85(4):e22225. PMID: 38879781
World J Biol Psychiatry

SEP-363856 attenuates CUMS-induced depression-like behaviours and reverses hippocampal neuronal injuries. [Abstract]

2024 Nov 29:1-18. PMID: 39610275
Mol Pharmacol

Trace amine-associated receptor 1 agonists differentially regulate dopamine transporter function. [Abstract]

2025 Jul 28;107(9):100064. PMID: 40840012
Synapse

Cellular-Resolution and Bulk-Fluorescence Recordings of Calcium Activity Yield Reciprocal Readouts of In Vivo Drug Efficacy. [Abstract]

2025 Mar;79(2):e70011. PMID: 40013455
patent

US20260034119A1.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dedic N, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019 Oct;371(1):1-14. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Ulotaront

11 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (11)
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ulotaront

MedChemExpress（MCE）の使用を引用している文献 Ulotaront

5-HT Receptor アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (11)

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Ulotaront 関連分類

HY-136109A 関連分類